Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19

NCT05172180 is registered in ClinicalTrials.gov with POLYSAN Scientific & Technological Pharmaceutical Company as lead sponsor.

NCT NCT05172180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05172180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19
Lead sponsor
POLYSAN Scientific & Technological Pharmaceutical Company
Phase
Observational
Overall status
Completed
Start date
December 1, 2020
Completion date
April 1, 2021
Enrollment
105 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19